{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:58:14Z","timestamp":1792123094584,"version":"4.4.0"},"reference-count":149,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Haematology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.beha.2025.101625","type":"journal-article","created":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T06:39:13Z","timestamp":1744871953000},"page":"101625","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Precision immunomodulation: Understanding and harnessing cytokine pathways to treat and prevent immune-related adverse events (irAEs)"],"prefix":"10.1016","volume":"38","author":[{"given":"Matthew J.","family":"Hadfield","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross D.","family":"Merkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherin J.","family":"Rouhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry L.","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.beha.2025.101625_bib1","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1093\/annonc\/mdv182","article-title":"A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors","volume":"26","author":"Chen","year":"2015","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.beha.2025.101625_bib2","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.beha.2025.101625_bib3","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41467-022-27960-2","article-title":"Immune-related adverse events and the balancing act of immunotherapy","volume":"13","author":"Conroy","year":"2022","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.beha.2025.101625_bib4","article-title":"Pro-inflammatory and anti-inflammatory interleukins in infectious diseases: a comprehensive review","volume":"9","author":"Al-Qahtani","year":"2024","journal-title":"Trav Med Infect Dis"},{"issue":"6","key":"10.1016\/j.beha.2025.101625_bib5","doi-asserted-by":"crossref","first-page":"633","DOI":"10.2174\/1381612003400533","article-title":"Anti-inflammatory cytokines and cytokine antagonists","volume":"6","author":"Standiford","year":"2000","journal-title":"Curr Pharm Des"},{"issue":"4","key":"10.1016\/j.beha.2025.101625_bib6","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/s41571-021-00588-9","article-title":"Harnessing cytokines and chemokines for cancer therapy","volume":"19","author":"Propper","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"10.1016\/j.beha.2025.101625_bib7","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/AIA.0b013e318034194e","article-title":"Cytokines, inflammation, and pain","volume":"45","author":"Zhang","year":"2007","journal-title":"Int Anesthesiol Clin"},{"issue":"8","key":"10.1016\/j.beha.2025.101625_bib8","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1007\/s00262-021-02855-1","article-title":"Cytokine changes during immune-related adverse events and corticosteroid treatment in melanoma patients receiving immune checkpoint inhibitors","volume":"70","author":"Tyan","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.beha.2025.101625_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1069999","article-title":"Serum cytokine levels for predicting immune-related adverse events and the clinical response in lung cancer treated with immunotherapy","volume":"12","author":"Zhao","year":"2022","journal-title":"Front Oncol"},{"issue":"20","key":"10.1016\/j.beha.2025.101625_bib10","doi-asserted-by":"crossref","DOI":"10.1172\/JCI176567","article-title":"Immune-related events in individuals with solid tumors on immunotherapy associate with Th17 and Th2 signatures","volume":"134","author":"Kao","year":"2024","journal-title":"J Clin Investig"},{"issue":"9","key":"10.1016\/j.beha.2025.101625_bib11","first-page":"1390","article-title":"A targetable type III immune response with increase of IL-17A expressing CD4(+) T cells is associated with immunotherapy-induced toxicity in melanoma","volume":"5","author":"Dimitriou","year":"2024","journal-title":"Nat Can"},{"issue":"3","key":"10.1016\/j.beha.2025.101625_bib12","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.cell.2020.06.001","article-title":"Molecular pathways of colon inflammation induced by cancer immunotherapy","volume":"182","author":"Luoma","year":"2020","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.beha.2025.101625_bib13","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ccell.2022.04.004","article-title":"Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity","volume":"40","author":"Hailemichael","year":"2022","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.beha.2025.101625_bib14","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1053\/j.gastro.2021.06.025","article-title":"Interferon-gamma-producing CD8(+) tissue resident memory T cells are a targetable hallmark of immune checkpoint inhibitor-colitis","volume":"161","author":"Sasson","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.beha.2025.101625_bib15","article-title":"Immunogenomic correlates of immune-related adverse events for anti-programmed cell death 1 therapy","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.beha.2025.101625_bib16","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1158\/0008-5472.CAN-11-3722","article-title":"Exploiting the mutanome for tumor vaccination","volume":"72","author":"Castle","year":"2012","journal-title":"Cancer Res"},{"issue":"75","key":"10.1016\/j.beha.2025.101625_bib17","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abn9644","article-title":"Autoreactive napsin A-specific T cells are enriched in lung tumors and inflammatory lung lesions during immune checkpoint blockade","volume":"7","author":"Berner","year":"2022","journal-title":"Sci Immunol."},{"issue":"3","key":"10.1016\/j.beha.2025.101625_bib18","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.jaad.2019.11.017","article-title":"Vitiligo under anti-programmed cell death-1 therapy is associated with increased survival in melanoma patients","volume":"82","author":"Nardin","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.beha.2025.101625_bib19","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1186\/s40425-019-0774-y","article-title":"Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature","volume":"7","author":"Safa","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"8","key":"10.1016\/j.beha.2025.101625_bib20","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.2337\/dbi18-0002","article-title":"Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors","volume":"67","author":"Stamatouli","year":"2018","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.beha.2025.101625_bib21","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1186\/s13046-020-01749-x","article-title":"The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors","volume":"39","author":"Jia","year":"2020","journal-title":"J Exp Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.beha.2025.101625_bib22","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.immuni.2014.12.005","article-title":"The coinhibitory receptor CTLA-4 controls B cell responses by modulating T follicular helper, T follicular regulatory, and T regulatory cells","volume":"41","author":"Sage","year":"2014","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.beha.2025.101625_bib23","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/intimm\/dxs098","article-title":"PD-1 is a novel regulator of human B-cell activation","volume":"25","author":"Thibult","year":"2013","journal-title":"Int Immunol"},{"issue":"2","key":"10.1016\/j.beha.2025.101625_bib24","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1172\/JCI96798","article-title":"Early B cell changes predict autoimmunity following combination immune checkpoint blockade","volume":"128","author":"Das","year":"2018","journal-title":"J Clin Investig"},{"issue":"9","key":"10.1016\/j.beha.2025.101625_bib25","first-page":"540","article-title":"Microbiota links to immunotherapy toxicity","volume":"21","author":"Seton-Rogers","year":"2021","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"10.1016\/j.beha.2025.101625_bib26","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1093\/annonc\/mdx108","article-title":"Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab","volume":"28","author":"Chaput","year":"2017","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.beha.2025.101625_bib27","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13073-024-01285-9","article-title":"Gut microbiome for predicting immune checkpoint blockade-associated adverse events","volume":"16","author":"Hu","year":"2024","journal-title":"Genome Med"},{"key":"10.1016\/j.beha.2025.101625_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.756872","article-title":"Intestinal microbiome associated with immune-related adverse events for patients treated with anti-PD-1 inhibitors, a real-world study","volume":"12","author":"Liu","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.beha.2025.101625_bib29","article-title":"Correlation of the gut microbiome and immune-related adverse events in gastrointestinal cancer patients treated with immune checkpoint inhibitors","volume":"13","author":"Zhang","year":"2023","journal-title":"Front Cell Infect Microbiol"},{"issue":"6371","key":"10.1016\/j.beha.2025.101625_bib30","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1126\/science.aao3290","article-title":"The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients","volume":"359","author":"Matson","year":"2018","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.beha.2025.101625_bib31","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.it.2012.10.003","article-title":"Drug targets in the cytokine universe for autoimmune disease","volume":"34","author":"Liu","year":"2013","journal-title":"Trends Immunol"},{"issue":"12","key":"10.1016\/j.beha.2025.101625_bib32","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.beha.2025.101625_bib33","doi-asserted-by":"crossref","first-page":"230","DOI":"10.6004\/jnccn.2020.0012","article-title":"NCCN guidelines insights: management of immunotherapy-related toxicities, version 1.2020","volume":"18","author":"Thompson","year":"2020","journal-title":"J Natl Compr Cancer Netw"},{"issue":"7","key":"10.1016\/j.beha.2025.101625_bib34","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002890","article-title":"Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors","volume":"9","author":"Guidon","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"36","key":"10.1016\/j.beha.2025.101625_bib35","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.beha.2025.101625_bib36","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/nri.2017.1","article-title":"Immune regulation by glucocorticoids","volume":"17","author":"Cain","year":"2017","journal-title":"Nat Rev Immunol"},{"issue":"Suppl 2","key":"10.1016\/j.beha.2025.101625_bib37","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1046\/j.1365-2036.1996.22164025.x","article-title":"Cytokine modulation by glucocorticoids: mechanisms and actions in cellular studies","volume":"10","author":"Brattsand","year":"1996","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.beha.2025.101625_bib38","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1183\/09031936.06.00125404","article-title":"Corticosteroid effects on cell signalling","volume":"27","author":"Barnes","year":"2006","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.beha.2025.101625_bib39","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.xphs.2023.10.016","article-title":"Fifty years of unraveling the clinical pharmacology of corticosteroids","volume":"113","author":"Kyler","year":"2024","journal-title":"J Pharmaceut Sci"},{"issue":"10","key":"10.1016\/j.beha.2025.101625_bib40","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1111\/1759-7714.13589","article-title":"Use of glucocorticoids in the management of immunotherapy-related adverse effects","volume":"11","author":"Wang","year":"2020","journal-title":"Thorac Cancer"},{"issue":"1","key":"10.1016\/j.beha.2025.101625_bib41","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s00018-005-5390-y","article-title":"Glucocorticoids in T cell apoptosis and function","volume":"63","author":"Herold","year":"2006","journal-title":"Cell Mol Life Sci"},{"issue":"3","key":"10.1016\/j.beha.2025.101625_bib42","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12030546","article-title":"Association of steroids use with survival in patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"12","author":"Petrelli","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"31","key":"10.1016\/j.beha.2025.101625_bib43","doi-asserted-by":"crossref","first-page":"3713","DOI":"10.1200\/JCO.24.00191","article-title":"Corticosteroids for immune-related adverse events and checkpoint inhibitor efficacy: analysis of six clinical trials","volume":"42","author":"Verheijden","year":"2024","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.beha.2025.101625_bib44","doi-asserted-by":"crossref","first-page":"5993","DOI":"10.1158\/1078-0432.CCR-21-1283","article-title":"Early use of high-dose glucocorticoid for the management of irAE is associated with poorer survival in patients with advanced melanoma treated with anti-PD-1 monotherapy","volume":"27","author":"Bai","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"18","key":"10.1016\/j.beha.2025.101625_bib45","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.1002\/cncr.31629","article-title":"High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma","volume":"124","author":"Faje","year":"2018","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.beha.2025.101625_bib46","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1084\/jem.20190738","article-title":"Selective inhibition of low-affinity memory CD8(+) T cells by corticosteroids","volume":"216","author":"Tokunaga","year":"2019","journal-title":"J Exp Med"},{"issue":"12","key":"10.1016\/j.beha.2025.101625_bib47","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1500108","article-title":"Contrasting impact of corticosteroids on anti-PD-1 immunotherapy efficacy for tumor histologies located within or outside the central nervous system","volume":"7","author":"Maxwell","year":"2018","journal-title":"OncoImmunology"},{"key":"10.1016\/j.beha.2025.101625_bib48","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12865-015-0103-2","article-title":"Dexamethasone enhances programmed cell death 1 (PD-1) expression during T cell activation: an insight into the optimum application of glucocorticoids in anti-cancer therapy","volume":"16","author":"Xing","year":"2015","journal-title":"BMC Immunol"},{"issue":"1","key":"10.1016\/j.beha.2025.101625_bib49","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1158\/1078-0432.CCR-20-2291","article-title":"Concurrent dexamethasone limits the clinical benefit of immune checkpoint blockade in glioblastoma","volume":"27","author":"Iorgulescu","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.beha.2025.101625_bib50","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.immuni.2020.08.005","article-title":"Endogenous glucocorticoid signaling regulates CD8(+) T cell differentiation and development of dysfunction in the tumor microenvironment","volume":"53","author":"Acharya","year":"2020","journal-title":"Immunity"},{"issue":"12","key":"10.1016\/j.beha.2025.101625_bib51","doi-asserted-by":"crossref","first-page":"5961","DOI":"10.21873\/anticanres.16106","article-title":"Impact of corticosteroids for IrAEs on the clinical outcome of immunotherapy in patients with NSCLC","volume":"42","author":"Shimomura","year":"2022","journal-title":"Anticancer Res"},{"issue":"Suppl 4","key":"10.1016\/j.beha.2025.101625_bib52","doi-asserted-by":"crossref","first-page":"S364","DOI":"10.21037\/tlcr.2019.06.06","article-title":"Impact of baseline steroids on efficacy of programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) blockade in patients with advanced non-small cell lung cancer","volume":"8","author":"Jove","year":"2019","journal-title":"Transl Lung Cancer Res"},{"issue":"4","key":"10.1016\/j.beha.2025.101625_bib53","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/CJI.0000000000000360","article-title":"Impact of baseline corticosteroids on immunotherapy efficacy in patients with advanced melanoma","volume":"44","author":"Kartolo","year":"2021","journal-title":"J Immunother"},{"issue":"28","key":"10.1016\/j.beha.2025.101625_bib54","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1200\/JCO.2018.79.0006","article-title":"Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer","volume":"36","author":"Arbour","year":"2018","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.beha.2025.101625_bib55","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14051296","article-title":"Is timing of steroid exposure prior to immune checkpoint inhibitor initiation associated with treatment outcomes in melanoma? A population-based study","volume":"14","author":"Nikita","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"22","key":"10.1016\/j.beha.2025.101625_bib56","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1200\/JCO.19.00189","article-title":"Immune checkpoint inhibitor outcomes for patients with non-small-cell lung cancer receiving baseline corticosteroids for palliative versus nonpalliative indications","volume":"37","author":"Ricciuti","year":"2019","journal-title":"J Clin Oncol"},{"issue":"28","key":"10.1016\/j.beha.2025.101625_bib57","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1200\/JCO.2015.60.8448","article-title":"Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at memorial sloan kettering cancer center","volume":"33","author":"Horvat","year":"2015","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.beha.2025.101625_bib58","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1007\/s12032-010-9606-0","article-title":"Continuous systemic corticosteroids do not affect the ongoing regression of metastatic melanoma for more than two years following ipilimumab therapy","volume":"28","author":"Harmankaya","year":"2011","journal-title":"Med Oncol"},{"issue":"8","key":"10.1016\/j.beha.2025.101625_bib59","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.annonc.2021.05.357","article-title":"The positive effect of immune checkpoint inhibitor-induced thyroiditis on overall survival accounting for immortal time bias: a retrospective cohort study of 6596 patients","volume":"32","author":"Street","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.beha.2025.101625_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102452","article-title":"Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into account immortal-time bias","volume":"110","author":"Kfoury","year":"2022","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"10.1016\/j.beha.2025.101625_bib61","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22052719","article-title":"The role of tumor necrosis factor alpha (TNF-alpha) in autoimmune disease and current TNF-alpha inhibitors in therapeutics","volume":"22","author":"Jang","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.beha.2025.101625_bib62","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/1097-0029(20000801)50:3<184::AID-JEMT2>3.0.CO;2-H","article-title":"TNF alpha and the TNF receptor superfamily: structure-function relationship(s)","volume":"50","author":"Idriss","year":"2000","journal-title":"Microsc Res Tech"},{"issue":"4","key":"10.1016\/j.beha.2025.101625_bib63","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41584-021-00584-4","article-title":"TNF in the era of immune checkpoint inhibitors: friend or foe?","volume":"17","author":"Chen","year":"2021","journal-title":"Nat Rev Rheumatol"},{"issue":"10","key":"10.1016\/j.beha.2025.101625_bib64","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1093\/ecco-jcc\/jjx081","article-title":"Colon immune-related adverse events: anti-CTLA-4 and anti-PD-1 blockade induce distinct immunopathological entities","volume":"11","author":"Coutzac","year":"2017","journal-title":"J Crohns Colitis"},{"issue":"7756","key":"10.1016\/j.beha.2025.101625_bib65","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/s41586-019-1162-y","article-title":"Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy","volume":"569","author":"Perez-Ruiz","year":"2019","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.beha.2025.101625_bib66","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s40425-018-0412-0","article-title":"Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis","volume":"6","author":"Johnson","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.beha.2025.101625_bib67","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s40425-019-0577-1","article-title":"Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis","volume":"7","author":"Abu-Sbeih","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.beha.2025.101625_bib68","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1186\/s40425-019-0711-0","article-title":"Concurrent therapy with immune checkpoint inhibitors and TNFalpha blockade in patients with gastrointestinal immune-related adverse events","volume":"7","author":"Badran","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"6","key":"10.1016\/j.beha.2025.101625_bib69","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007195","article-title":"Concurrent immune checkpoint inhibition and selective immunosuppressive therapy in patients with immune-related enterocolitis","volume":"11","author":"Badran","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"9","key":"10.1016\/j.beha.2025.101625_bib70","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1158\/1078-0432.CCR-19-3322","article-title":"Association of anti-TNF with decreased survival in steroid refractory ipilimumab and anti-PD1-treated patients in the Dutch melanoma treatment Registry","volume":"26","author":"Verheijden","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.beha.2025.101625_bib71","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1158\/1078-0432.CCR-20-0387","article-title":"TNFalpha blockade in checkpoint inhibition: the good, the bad, or the ugly?","volume":"26","author":"Weber","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.beha.2025.101625_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114172","article-title":"Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma","volume":"207","author":"Verheijden","year":"2024","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.beha.2025.101625_bib73","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1499478","article-title":"Impact of steroid-sparing immunosuppressive agents on tumor outcome in the context of cancer immunotherapy with highlight on melanoma: a systematic literature review and meta-analysis","volume":"15","author":"Strouse","year":"2024","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.beha.2025.101625_bib74","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1158\/1078-0432.CCR-20-3449","article-title":"Combining nivolumab and ipilimumab with infliximab or certolizumab in patients with advanced melanoma: first results of a phase Ib clinical trial","volume":"27","author":"Montfort","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.beha.2025.101625_bib75","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007530","article-title":"New perspectives in cancer immunotherapy: targeting IL-6 cytokine family","volume":"11","author":"Soler","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"10","key":"10.1016\/j.beha.2025.101625_bib76","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a016295","article-title":"IL-6 in inflammation, immunity, and disease","volume":"6","author":"Tanaka","year":"2014","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"5","key":"10.1016\/j.beha.2025.101625_bib77","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1038\/s41591-024-02895-x","article-title":"Single-cell transcriptomic analyses reveal distinct immune cell contributions to epithelial barrier dysfunction in checkpoint inhibitor colitis","volume":"30","author":"Thomas","year":"2024","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.beha.2025.101625_bib78","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-006814","article-title":"Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events","volume":"11","author":"Fa'ak","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.beha.2025.101625_bib79","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ejca.2021.08.031","article-title":"Interleukin-6 blockade for prophylaxis and management of immune-related adverse events in cancer immunotherapy","volume":"157","author":"Dimitriou","year":"2021","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.beha.2025.101625_bib80","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1177\/1078155217745144","article-title":"Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade","volume":"25","author":"Stroud","year":"2019","journal-title":"J Oncol Pharm Pract"},{"issue":"9","key":"10.1016\/j.beha.2025.101625_bib81","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005111","article-title":"COLAR: open-label clinical study of IL-6 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis and arthritis","volume":"10","author":"Holmstroem","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.beha.2025.101625_bib82","doi-asserted-by":"crossref","first-page":"9538","DOI":"10.1200\/JCO.2024.42.16_suppl.9538","article-title":"Interleukin-6 receptor blockade with tocilizumab to reduce immune-related toxicity with ipilimumab and nivolumab in metastatic melanoma","volume":"42","author":"Weber","year":"2024","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.beha.2025.101625_bib83","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1200\/JCO.18.01998","article-title":"Evaluation of two dosing regimens for nivolumab in combination with ipilimumab in patients with advanced melanoma: results from the phase IIIb\/IV CheckMate 511 trial","volume":"37","author":"Lebbe","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2025.101625_bib84","doi-asserted-by":"crossref","first-page":"9553","DOI":"10.1200\/JCO.2024.42.16_suppl.9553","article-title":"Phase II trial of weekly or bi-weekly tocilizumab with ipilimumab and nivolumab in advanced melanoma: clinical outcomes and biomarker analysis","author":"Anouti","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.beha.2025.101625_bib85","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41392-023-01620-3","article-title":"The IL-17 family in diseases: from bench to bedside","volume":"8","author":"Huangfu","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"10.1016\/j.beha.2025.101625_bib86","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20190456","article-title":"Targeting the interleukin-17 immune axis for cancer immunotherapy","volume":"217","author":"Vitiello","year":"2020","journal-title":"J Exp Med"},{"issue":"9","key":"10.1016\/j.beha.2025.101625_bib87","first-page":"1292","article-title":"Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma","volume":"4","author":"Varaljai","year":"2023","journal-title":"Nat Can"},{"issue":"3","key":"10.1016\/j.beha.2025.101625_bib88","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008482","article-title":"Inhibition of IL-25\/IL-17RA improves immune-related adverse events of checkpoint inhibitors and reveals antitumor activity","volume":"12","author":"Hu","year":"2024","journal-title":"J Immunother Cancer"},{"issue":"4","key":"10.1016\/j.beha.2025.101625_bib89","doi-asserted-by":"crossref","first-page":"696","DOI":"10.4049\/jimmunol.2200244","article-title":"Inhibition of IL-17A protects against thyroid immune-related adverse events while preserving checkpoint inhibitor antitumor efficacy","volume":"209","author":"Lechner","year":"2022","journal-title":"J Immunol"},{"key":"10.1016\/j.beha.2025.101625_bib90","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ejca.2020.10.006","article-title":"Evidence for interleukin 17 involvement in severe immune-related neuroendocrine toxicity","volume":"141","author":"Mazzarella","year":"2020","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.beha.2025.101625_bib91","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1158\/2326-6066.CIR-18-0682","article-title":"IL17A blockade successfully treated psoriasiform dermatologic toxicity from immunotherapy","volume":"7","author":"Johnson","year":"2019","journal-title":"Cancer Immunol Res"},{"issue":"8","key":"10.1016\/j.beha.2025.101625_bib92","doi-asserted-by":"crossref","first-page":"593","DOI":"10.2217\/imt-2021-0274","article-title":"Successful use of secukinumab in two melanoma patients with immune checkpoint inhibitor-induced inflammatory arthropathy","volume":"14","author":"Ma","year":"2022","journal-title":"Immunotherapy"},{"issue":"1","key":"10.1016\/j.beha.2025.101625_bib93","doi-asserted-by":"crossref","first-page":"40","DOI":"10.2174\/187152809787582507","article-title":"The IL-12 family of cytokines in infection, inflammation and autoimmune disorders","volume":"8","author":"Gee","year":"2009","journal-title":"Inflamm Allergy - Drug Targets"},{"issue":"9","key":"10.1016\/j.beha.2025.101625_bib94","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/j.immuni.2022.08.007","article-title":"Induction of a colitogenic phenotype in Th1-like cells depends on interleukin-23 receptor signaling","volume":"55","author":"Pawlak","year":"2022","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.beha.2025.101625_bib95","doi-asserted-by":"crossref","first-page":"6719","DOI":"10.1038\/s41467-023-41798-2","article-title":"Immune checkpoint inhibitor-induced colitis is mediated by polyfunctional lymphocytes and is dependent on an IL23\/IFNgamma axis","volume":"14","author":"Lo","year":"2023","journal-title":"Nat Commun"},{"issue":"7","key":"10.1016\/j.beha.2025.101625_bib96","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009345","article-title":"Prophylactic IL-23 blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy","volume":"12","author":"Ju","year":"2024","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.beha.2025.101625_bib97","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2165\/00063030-200923010-00006","article-title":"Ustekinumab","volume":"23","author":"Weber","year":"2009","journal-title":"BioDrugs"},{"issue":"11","key":"10.1016\/j.beha.2025.101625_bib98","doi-asserted-by":"crossref","DOI":"10.3390\/ph16111548","article-title":"IL12\/23 blockade with ustekinumab as a treatment for immune-related cutaneous adverse events","volume":"16","author":"Gu","year":"2023","journal-title":"Pharmaceuticals"},{"issue":"9","key":"10.1016\/j.beha.2025.101625_bib99","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000033061","article-title":"Ustekinumab for steroid-refractory pancolitis in a biologically naive child: a case report and literature review","volume":"102","author":"Alhalabi","year":"2023","journal-title":"Medicine (Baltim)"},{"issue":"9","key":"10.1016\/j.beha.2025.101625_bib100","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.14309\/ajg.0000000000002332","article-title":"IL12\/23 blockade for refractory immune-mediated colitis: 2-center experience","volume":"118","author":"Shirwaikar","year":"2023","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.beha.2025.101625_bib101","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008232","article-title":"Management of infliximab refractory immune checkpoint inhibitor gastrointestinal toxicity: a multicenter case series","volume":"12","author":"Harvey","year":"2024","journal-title":"J Immunother Cancer"},{"issue":"9","key":"10.1016\/j.beha.2025.101625_bib102","doi-asserted-by":"crossref","first-page":"582","DOI":"10.6004\/jnccn.2024.0057","article-title":"NCCN guidelines(R) insights: management of immunotherapy-related toxicities, version 2.2024","volume":"22","author":"Thompson","year":"2024","journal-title":"J Natl Compr Cancer Netw"},{"issue":"6","key":"10.1016\/j.beha.2025.101625_bib103","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.beha.2025.101625_bib104","doi-asserted-by":"crossref","first-page":"888","DOI":"10.3389\/fimmu.2018.00888","article-title":"Tuning the cytokine responses: an update on interleukin (IL)-4 and IL-13 receptor complexes","volume":"9","author":"Junttila","year":"2018","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.beha.2025.101625_bib105","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/cea.13491","article-title":"Mechanisms of dupilumab","volume":"50","author":"Harb","year":"2020","journal-title":"Clin Exp Allergy"},{"issue":"8","key":"10.1016\/j.beha.2025.101625_bib106","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1001\/jamadermatol.2022.1624","article-title":"Association of bullous pemphigoid with immune checkpoint inhibitor therapy in patients with cancer: a systematic review","volume":"158","author":"Asdourian","year":"2022","journal-title":"JAMA Dermatol"},{"issue":"9","key":"10.1016\/j.beha.2025.101625_bib107","doi-asserted-by":"crossref","DOI":"10.5070\/D327955136","article-title":"Dupilumab for the treatment of nivolumab-induced bullous pemphigoid: a case report and review of the literature","volume":"27","author":"Klepper","year":"2021","journal-title":"Dermatol Online J"},{"issue":"8","key":"10.1016\/j.beha.2025.101625_bib108","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15623","article-title":"Dupilumab for the treatment of pembrolizumab-induced bullous pemphigoid: a case report","volume":"35","author":"Pop","year":"2022","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.beha.2025.101625_bib109","volume":"vol. 11","author":"Fournier","year":"2023"},{"issue":"5","key":"10.1016\/j.beha.2025.101625_bib110","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1046\/j.0022-202x.2001.01505.x","article-title":"Skin-homing interleukin-4 and -13-producing cells contribute to bullous pemphigoid: remission of disease is associated with increased frequency of interleukin-10-producing cells","volume":"117","author":"Teraki","year":"2001","journal-title":"J Invest Dermatol"},{"issue":"6","key":"10.1016\/j.beha.2025.101625_bib111","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007324","article-title":"Management of immune-related cutaneous adverse events with dupilumab","volume":"11","author":"Kuo","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"10","key":"10.1016\/j.beha.2025.101625_bib112","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/s41568-020-0283-9","article-title":"A new dawn for eosinophils in the tumour microenvironment","volume":"20","author":"Grisaru-Tal","year":"2020","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/j.beha.2025.101625_bib113","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nri3786","article-title":"Type 2 inflammation in asthma--present in most, absent in many","volume":"15","author":"Fahy","year":"2015","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"10.1016\/j.beha.2025.101625_bib114","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","article-title":"Immune-checkpoint inhibitors: long-term implications of toxicity","volume":"19","author":"Johnson","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"issue":"14","key":"10.1016\/j.beha.2025.101625_bib115","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241411849","article-title":"Neoadjuvant immunotherapy: a promising new standard of care","volume":"24","author":"Boydell","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.beha.2025.101625_bib116","article-title":"Nanovaccines for cancer immunotherapy: focusing on complex formation between adjuvant and antigen","volume":"117","author":"Hashemi","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.beha.2025.101625_bib117","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1438587","article-title":"Corrigendum: biomarkers and computational models for predicting efficacy to tumor ICI immunotherapy","volume":"15","author":"Qin","year":"2024","journal-title":"Front Immunol"},{"issue":"35","key":"10.1016\/j.beha.2025.101625_bib118","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1200\/JCO.24.00326","article-title":"Enhancing precision in detecting severe immune-related adverse events: comparative analysis of large language models and international classification of disease codes in patient records","volume":"42","author":"Sun","year":"2024","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.beha.2025.101625_bib119","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009999","article-title":"Use of artificial intelligence chatbots in clinical management of immune-related adverse events","volume":"12","author":"Zhou","year":"2024","journal-title":"J Immunother Cancer"},{"issue":"11","key":"10.1016\/j.beha.2025.101625_bib120","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12113446","article-title":"Multidisciplinary clinical approach to cancer patients with immune-related adverse events induced by checkpoint inhibitors","volume":"12","author":"Londono","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"9","key":"10.1016\/j.beha.2025.101625_bib121","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1111\/apt.17201","article-title":"Safety and efficacy of infliximab and corticosteroid therapy in checkpoint inhibitor-induced colitis","volume":"56","author":"Dahl","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.beha.2025.101625_bib122","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1111\/apt.15998","article-title":"Systematic review with meta-analysis: effectiveness of anti-inflammatory therapy in immune checkpoint inhibitor-induced enterocolitis","volume":"52","author":"Ibraheim","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"issue":"11","key":"10.1016\/j.beha.2025.101625_bib123","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003277","article-title":"Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study","volume":"9","author":"Zou","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"2","key":"10.1016\/j.beha.2025.101625_bib124","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001488","article-title":"Clinicopathological characteristics and management of colitis with anti-PD1 immunotherapy alone or in combination with ipilimumab","volume":"8","author":"Nahar","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"4","key":"10.1016\/j.beha.2025.101625_bib125","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2019-000585","article-title":"Five-year review of corticosteroid duration and complications in the management of immune checkpoint inhibitor-related diarrhoea and colitis in advanced melanoma","volume":"5","author":"Favara","year":"2020","journal-title":"ESMO Open"},{"issue":"4","key":"10.1016\/j.beha.2025.101625_bib126","doi-asserted-by":"crossref","first-page":"e350","DOI":"10.1093\/oncolo\/oyac019","article-title":"Efficacy of infliximab dose escalation in patients with refractory immunotherapy-related colitis: a case series","volume":"27","author":"Harris","year":"2022","journal-title":"Oncologist"},{"issue":"7","key":"10.1016\/j.beha.2025.101625_bib127","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1136\/ard-2023-223885","article-title":"Comparative safety and effectiveness of TNF inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritis","volume":"82","author":"Bass","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.beha.2025.101625_bib128","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1111\/jgh.16349","article-title":"Serious immune-related upper gastrointestinal toxicity of immune checkpoint inhibitors: a multicenter case series","volume":"38","author":"Bresteau","year":"2023","journal-title":"J Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.beha.2025.101625_bib129","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008074","article-title":"Infliximab in steroid-refractory immune-related hepatitis does not demonstrate hepatotoxicity and may shorten time on steroids","volume":"12","author":"Burri","year":"2024","journal-title":"J Immunother Cancer"},{"issue":"4","key":"10.1016\/j.beha.2025.101625_bib130","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1136\/flgastro-2018-101146","article-title":"Immunotherapy-related hepatitis: real-world experience from a tertiary centre","volume":"10","author":"Cheung","year":"2019","journal-title":"Frontline Gastroenterol"},{"issue":"2","key":"10.1016\/j.beha.2025.101625_bib131","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1177\/10600280221094330","article-title":"Management of steroid-refractory gastrointestinal immune-related adverse events","volume":"57","author":"Brongiel","year":"2023","journal-title":"Ann Pharmacother"},{"issue":"9","key":"10.1016\/j.beha.2025.101625_bib132","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15092538","article-title":"Steroid-refractory immune-related adverse events induced by checkpoint inhibitors","volume":"15","author":"Tomsitz","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.beha.2025.101625_bib133","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103632","article-title":"A 1-year follow-up study on checkpoint inhibitor-induced colitis: results from a European consortium","volume":"9","author":"Lenti","year":"2024","journal-title":"ESMO Open"},{"issue":"11","key":"10.1016\/j.beha.2025.101625_bib134","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1007\/s12012-024-09918-6","article-title":"Steroid-refractory myocarditis induced by immune checkpoint inhibitor responded to infliximab: report of two cases and literature review","volume":"24","author":"Tan","year":"2024","journal-title":"Cardiovasc Toxicol"},{"issue":"4","key":"10.1016\/j.beha.2025.101625_bib135","doi-asserted-by":"crossref","first-page":"172","DOI":"10.36401\/JIPO-20-22","article-title":"Role of infliximab in immune checkpoint inhibitor-induced pneumonitis","volume":"3","author":"Lai","year":"2020","journal-title":"J Immunother Precis Oncol"},{"key":"10.1016\/j.beha.2025.101625_bib136","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2018-225937","article-title":"Severe pneumonitis refractory to steroids following anti-PD-1 immunotherapy","volume":"2018","author":"Andruska","year":"2018","journal-title":"BMJ Case Rep"},{"issue":"1","key":"10.1016\/j.beha.2025.101625_bib137","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1877415","article-title":"Infliximab for the treatment of patients with checkpoint inhibitor-associated acute tubular interstitial nephritis","volume":"10","author":"Lin","year":"2021","journal-title":"OncoImmunology"},{"key":"10.1016\/j.beha.2025.101625_bib138","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1421684","article-title":"Tumor necrosis factor inhibitors enhance corticosteroid therapy for Stevens-Johnson syndrome and toxic epidermal necrolysis linked to immune checkpoint inhibitors: a prospective study","volume":"15","author":"He","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.beha.2025.101625_bib139","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.2147\/JIR.S454673","article-title":"Emerging insights into stevens-johnson syndrome and toxic epidermal necrolysis induced by immune checkpoint inhibitor and tumor-targeted therapy","volume":"17","author":"Lin","year":"2024","journal-title":"J Inflamm Res"},{"key":"10.1016\/j.beha.2025.101625_bib140","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ejca.2022.11.035","article-title":"Phase 2 study of ipilimumab, nivolumab, and tocilizumab combined with stereotactic body radiotherapy in patients with refractory pancreatic cancer (TRIPLE-R)","volume":"180","author":"Chen","year":"2023","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.beha.2025.101625_bib141","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.annonc.2024.08.2340","article-title":"Tocilizumab provides dual benefits in treating immune checkpoint inhibitor-associated arthritis and preventing relapse during ICI rechallenge: the TAPIR study","volume":"36","author":"Petit","year":"2025","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.beha.2025.101625_bib142","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1136\/annrheumdis-2017-211560","article-title":"Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series","volume":"76","author":"Kim","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.beha.2025.101625_bib143","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13010255","article-title":"The clinical analysis of checkpoint inhibitor pneumonitis with different severities in lung cancer patients: a retrospective study","volume":"13","author":"Huang","year":"2024","journal-title":"J Clin Med"},{"issue":"2","key":"10.1016\/j.beha.2025.101625_bib144","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jtho.2020.09.007","article-title":"Personalized cytokine-directed therapy with tocilizumab for refractory immune checkpoint inhibitor-related cholangiohepatitis","volume":"16","author":"Moi","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.beha.2025.101625_bib145","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.807050","article-title":"Cytokine release syndrome in cancer patients receiving immune checkpoint inhibitors: a case series of 25 patients and review of the literature","volume":"13","author":"Tay","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.beha.2025.101625_bib146","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcmd.2024.102896","article-title":"Hemophagocytic lymphohistiocytosis associated with immune checkpoint inhibitor use: a review of the current knowledge and future directions","volume":"110","author":"Walmsley","year":"2025","journal-title":"Blood Cells Mol Dis"},{"issue":"4","key":"10.1016\/j.beha.2025.101625_bib147","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/CMR.0000000000000969","article-title":"Tocilizumab in the treatment of steroid refractory immune-related hepatotoxicity: a case series and review of the literature","volume":"34","author":"Ozluk","year":"2024","journal-title":"Melanoma Res"},{"key":"10.1016\/j.beha.2025.101625_bib148","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ejim.2021.07.016","article-title":"Tocilizumab for the treatment of immune-related adverse events: a systematic literature review and a multicentre case series","volume":"93","author":"Campochiaro","year":"2021","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.beha.2025.101625_bib149","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejca.2018.09.033","article-title":"Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors","volume":"106","author":"Moreira","year":"2019","journal-title":"Eur J Cancer"}],"updated-by":[{"DOI":"10.1016\/j.beha.2025.101648","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000}}],"container-title":["Best Practice &amp; Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692625000301?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692625000301?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T07:07:11Z","timestamp":1753081631000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692625000301"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":149,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S1521692625000301"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2025.101625","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Precision immunomodulation: Understanding and harnessing cytokine pathways to treat and prevent immune-related adverse events (irAEs)","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2025.101625","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101625"}}